<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666783</url>
  </required_header>
  <id_info>
    <org_study_id>2006L01595</org_study_id>
    <nct_id>NCT00666783</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients</brief_title>
  <official_title>A Phase II, Multicenter,Double-Blind, Randomized Trial of Palonosetron Compared With Granisetron in Preventing Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting in the Chinese Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <brief_summary>
    <textblock>
      This clinical study was designed to demonstrate that a single, intravenous dose of
      palonosetron 0.25 mg was not inferior to granisetron 3 mg in preventing acute and delayed
      CINV and was also well tolerated in the Chinese cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Chemotherapy-Induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>PAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive any of the following cytotoxic agents based combination chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GRA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>receive any of the following cytotoxic agents based combination chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>palonosetron</intervention_name>
    <description>receive a single, intravenous dose of palonosetron 0.25 mg, 30 minutes before receiving highly emetogenic chemotherapy.</description>
    <arm_group_label>PAL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granisetron</intervention_name>
    <description>receive a single, intravenous dose of granisetron 3 mg, 30 minutes before chemotherapy.</description>
    <arm_group_label>GRA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age ranging from 18 yrs to 70 yrs, with histologically or
             cytologically confirmed malignant disease

          -  naive to chemotherapy or nonnaive with an interval of at least 14 days to the last one

          -  Karnofsky index more than 70% and anticipated survival time more than 90 days

          -  Scheduled to receive any of the following cytotoxic agents based combination
             chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2) on study Day 1 and the
             chemotherapy should be accomplished on study Day 1

          -  No emetic episodes and antiemetic medication during the 24 hours preceding
             chemotherapy administration

          -  Adequate organ functions(No impairment to renal, hepatic, cardiac or bone marrow
             function )

          -  Use of reliable contraceptive measures (for females of childbearing potential) and
             negative pregnancy test at baseline visit

          -  Provision of written informed consent

        Exclusion Criteria:

          -  Inability to understand or cooperate with study procedures

          -  Receipt of investigational drugs 30 days before study entry

          -  Scheduled to receive any drug with antiemetic efficacy from 24 hrs before to 5 days
             after treatment

          -  Contraindications to 5-HT3 receptor antagonists

          -  Woman Patient with Pregnancy or lactation

          -  Diagnosed with hypertension or severe infectious diseases

          -  Obstructive symptom of gastrointestinal tract

          -  Symptomatic brain metastasis or mental dysfunction

          -  Baseline QTc &gt; 500 ms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xijng Hospital</name>
      <address>
        <city>Xi,an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2008</study_first_posted>
  <last_update_submitted>April 24, 2008</last_update_submitted>
  <last_update_submitted_qc>April 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Xijing Hospital</name_title>
    <organization>Clinical trial center of Xijing Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palonosetron</mesh_term>
    <mesh_term>Granisetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

